Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Hou

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Pharmacoepidemiology and Drug Safety|February 19, 2020
Translating claims-based CHA<sub>2</sub> DS<sub>2</sub> -VaSc and HAS-BLED to ICD-10-CM: Impacts of mapping strategiesMichael Webster-Clark, Ting-Ying Huang, Laura Hou, et al.
Journal of Shoulder and Elbow Surgery|June 11, 2016
The risk of nerve injury during anatomical and reverse total shoulder arthroplasty: an intraoperative neuromonitoring studyRobert L Parisien, Paul H Yi, Laura Hou, et al.
Clinical Orthopaedics and Related Research|February 26, 2016
The ACS NSQIP Risk Calculator Is a Fair Predictor of Acute Periprosthetic Joint InfectionNathaniel C Wingert, James Gotoff, Edgardo Parrilla, et al.
American Journal of Obstetrics and Gynecology|September 5, 2021
Incidence of severe uterine bleeding outcomes among oral anticoagulant users and nonusersTing-Ying Huang, Laura Hou, Abby Anderson, et al.
Pharmacoepidemiology and Drug Safety|November 19, 2019
Quantifying how small variations in design elements affect risk in an incident cohort study in claimsRima Izem, Ting-Ying Huang, Laura Hou, et al.
American Journal of Obstetrics and Gynecology|November 29, 2020
Incidence of uterine bleeding following oral anticoagulant use in Food and Drug Administration's Sentinel SystemAbby Anderson, Audrey Gassman, Laura Hou, et al.
Pharmacoepidemiology and Drug Safety|November 4, 2022
A new analytic tool for assessing the impact of the US Food and Drug Administration regulatory actionsChristine Y Lu, Laura Hou, Joy Kolonoski, et al.
Pharmacoepidemiology and Drug Safety|October 13, 2024
Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer RiskCheng Chen, Efe Eworuke, Ashish Rai, et al.
American Journal of Epidemiology|July 8, 2024
A simple Cox approach to estimating risk ratios without sharing individual-level data in multisite studiesDi Shu, Guangyong Zou, Laura Hou, et al.
Drug Safety|May 20, 2021
Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and WarfarinEfe Eworuke, Laura Hou, Rongmei Zhang, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Pharmacoepidemiology and Drug Safety|February 19, 2020
Translating claims-based CHA<sub>2</sub> DS<sub>2</sub> -VaSc and HAS-BLED to ICD-10-CM: Impacts of mapping strategiesMichael Webster-Clark, Ting-Ying Huang, Laura Hou, et al.
Journal of Shoulder and Elbow Surgery|June 11, 2016
The risk of nerve injury during anatomical and reverse total shoulder arthroplasty: an intraoperative neuromonitoring studyRobert L Parisien, Paul H Yi, Laura Hou, et al.
Clinical Orthopaedics and Related Research|February 26, 2016
The ACS NSQIP Risk Calculator Is a Fair Predictor of Acute Periprosthetic Joint InfectionNathaniel C Wingert, James Gotoff, Edgardo Parrilla, et al.
American Journal of Obstetrics and Gynecology|September 5, 2021
Incidence of severe uterine bleeding outcomes among oral anticoagulant users and nonusersTing-Ying Huang, Laura Hou, Abby Anderson, et al.
Pharmacoepidemiology and Drug Safety|November 19, 2019
Quantifying how small variations in design elements affect risk in an incident cohort study in claimsRima Izem, Ting-Ying Huang, Laura Hou, et al.
American Journal of Obstetrics and Gynecology|November 29, 2020
Incidence of uterine bleeding following oral anticoagulant use in Food and Drug Administration's Sentinel SystemAbby Anderson, Audrey Gassman, Laura Hou, et al.
Pharmacoepidemiology and Drug Safety|November 4, 2022
A new analytic tool for assessing the impact of the US Food and Drug Administration regulatory actionsChristine Y Lu, Laura Hou, Joy Kolonoski, et al.
Pharmacoepidemiology and Drug Safety|October 13, 2024
Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer RiskCheng Chen, Efe Eworuke, Ashish Rai, et al.
American Journal of Epidemiology|July 8, 2024
A simple Cox approach to estimating risk ratios without sharing individual-level data in multisite studiesDi Shu, Guangyong Zou, Laura Hou, et al.
Drug Safety|May 20, 2021
Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and WarfarinEfe Eworuke, Laura Hou, Rongmei Zhang, et al.
Pageof 3